Merck's (MRK) Enflonsia has been approved by the UK's Medicines and Healthcare products Regulatory Agency for the prevention of respiratory syncytial virus lower respiratory tract disease in newborns and infants, the regulator said Wednesday.
The indication is for newborns and infants up to 12 months of age throughout their first RSV season, the regulator said.
The drug is a single injection administered once by a healthcare professional, the regulator said.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments